Evidence map›Paper›PMID 29173081›Full record

ReviewViral immunology2018

Varicella Virus Vaccination in the United States.

Jana Shaw, Anne A Gershon

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Viral immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Assessing and restoring adaptive immunity to HSV, VZV, and HHV-6 in solid organ and hematopoietic cell transplant recipients.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Jana Shaw1 Department of Pediatrics, Upstate Medical Center , Syracuse, New York.
Anne A Gershon2 Department of Pediatrics, Columbia University College of Physicians and Surgeons , New York, New York.
Columbia University · USSUNY Upstate Medical University · US

Funding

VZV in the enteric nervous system: pathogenesis and consequencesR01DK093094 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MICHAEL D GERSHON, Anne A. Gershon · 2011 to 2026
$5.9M
NIDDK NIH HHS R01 DK093094
6 · The paper itself

Abstract

Varicella zoster virus (VZV) is the cause of chickenpox (varicella) and shingles (zoster), and was once responsible for over 4 million infections in the United States annually. The development of a live attenuated VZV vaccine was initially viewed with extreme skepticism. Nonetheless, a VZV vaccine was developed in the 1970s by Takahashi and his colleagues in Japan and was eventually licensed in the US. It is now known to be one of the safest and most effective vaccines available and is administered worldwide. Here are described important factors that contributed to the successful research and licensure of the highly successful VZV vaccine.

Indexed as

ChickenpoxChickenpox VaccineDrug ApprovalHerpesvirus 3, HumanHerpes ZosterHerpes Zoster VaccineHumansUnited StatesVaccines, AttenuatedChickenpox VaccineHerpes Zoster VaccineVaccines, Attenuatedlatent virusvaricella vaccinevaricella zoster virus

Identifiers

PMID29173081
PMCPMC5863082
OpenAlexW2770370380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.